Annual report pursuant to Section 13 and 15(d)

Note 8 - Inventory

v3.8.0.1
Note 8 - Inventory
 12 Months Ended
Dec. 31, 2017
Notes to Financial Statements  
Inventory Disclosure [Text Block]
8
.
Inventory
 
The components of net inventory at
December 31,
201
7
and
2016,
net of reserves of
$748
and
$0,
respectively, are as follows:
 
   
2017
    
2016
  
Materials
   $
—
     $
94,500
  
Work-in-process
    
—
      
1,708
  
Finished goods
    
748
      
—
  
Reserves
    
(748
)
    
—
  
Total inventory, net   $
—
     $
96,208
  
 
During
2016,
we utilized
$131,000
of
Tc99m
tilmanocept inventory for clinical study and product development purposes. Also during
2016,
we recorded obsolescence reserves of
$43,000
of
Tc99m
tilmanocept inventory related to specific lots that expired or were nearing product expiry and therefore were
no
longer expected to be sold. See Note
1
(h).
 
Inventory in the amount of
$1,374,618
as of
December 31, 2016
has been reclassified to current assets associated with discontinued operations. See Note
3.